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Abstract 
Background: Perrault syndrome is a rare autosomal recessive disorder that is characterized by the association of sen‑
sorineural hearing impairment and ovarian dysgenesis in females, whereas males have only hearing impairment. In 
some cases, patients present with a diversity of neurological signs. To date, mutations in six genes are known to cause 
Perrault syndrome, but they do not explain all clinically‑diagnosed cases. In addition, the number of reported cases 
and the spectra of mutations are still small to establish conclusive genotype–phenotype correlations.
Methods: Affected siblings from family SH19, who presented with features that were suggestive of Perrault syn‑
drome, were subjected to audiological, neurological and gynecological examination. The genetic study included 
genotyping and haplotype analysis for microsatellite markers close to the genes involved in Perrault syndrome, 
whole‑exome sequencing, and Sanger sequencing of the coding region of the TWNK gene.
Results: Three siblings from family SH19 shared similar clinical features: childhood‑onset bilateral sensorineural 
hearing impairment, which progressed to profound deafness in the second decade of life; neurological signs (spi‑
nocerebellar ataxia, polyneuropathy), with onset in the fourth decade of life in the two females and at age 20 years 
in the male; gonadal dysfunction with early cessation of menses in the two females. The genetic study revealed two 
compound heterozygous pathogenic mutations in the TWNK gene in the three affected subjects: c.85C>T (p.Arg29*), 
previously reported in a case of hepatocerebral syndrome; and a novel missense mutation, c.1886C>T (p.Ser629Phe). 
Mutations segregated in the family according to an autosomal recessive inheritance pattern.
Conclusions: Our results further illustrate the utility of genetic testing as a tool to confirm a tentative clinical diagno‑
sis of Perrault syndrome. Studies on genotype–phenotype correlation from the hitherto reported cases indicate that 
patients with Perrault syndrome caused by TWNK mutations will manifest neurological signs in adulthood. Molecular 
and clinical characterization of novel cases of recessive disorders caused by TWNK mutations is strongly needed to 
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Background
Perrault syndrome (PRLTS) is an autosomal recessive 
genetic disorder that is characterized by the association 
of sensorineural hearing impairment and ovarian dys-
genesis in females [1, 2]. Affected males may have only an 
apparently non-syndromic hearing impairment. In some 
cases, males and females present with neurological signs, 
including progressive sensory and motor peripheral neu-
ropathy, cerebellar ataxia, and mild intellectual disability 
[2, 3]. Accordingly, PRLTS is classified clinically into two 
types, with or without neurologic manifestations (types 
II and I, respectively). PRLTS is a rare disease, although 
no accurate data on its prevalence are available. Given 
that hearing impairment may be the only clinical sign in 
males, underascertainment is likely [2].
PRLTS is genetically heterogeneous. To date, mutations 
in six genes are known to cause different genetic types of 
the syndrome (Table 1).
HSD17B4, the first gene whose involvement in PRLTS 
was reported [4], encodes 17β-hydroxysteroid dehydro-
genase type 4, a peroxisomal multifunctional enzyme 
involved in the fatty acid β-oxidation pathway and ster-
oid metabolism. The other five genes code for proteins 
that play roles in mitochondrial function. HARS2 [5] 
and LARS2 [6] code for mitochondrial histidyl-tRNA 
synthetase 2 and leucyl-tRNA synthetase 2, respectively. 
CLPP [7] encodes an endopeptidase subunit of a mito-
chondrial ATP-dependent proteolytic complex. TWNK 
[8] encodes Twinkle, a DNA helicase that is essential 
for the replication of the mitochondrial genome. Finally, 
ERAL1 [9] codes for a GTPase that acts as a chaperone 
for the 12S mitochondrial rRNA, and so it contributes 
to the proper assembly of the 28S small mitochondrial 
ribosomal subunit. After screening for mutations in 
these six genes, molecular diagnosis is not reached in 
approximately 60% of individuals with PRLTS [2], which 
indicates that its genetic bases are still far from being 
completely understood.
The number of cases with mutations in each of the six 
known genes is still small to establish definite genotype–
phenotype correlations. So far, all patients with PRLTS 
due to mutations in HSD17B4 and TWNK present with 
neurological manifestations (clinical type II) [4, 8, 10–
14]. Mutations in CLPP or LARS2 may result in clinical 
types I or II [6, 7, 12, 14–20]. Finally, no neurological 
manifestations have been reported to date in patients 
with mutations in HARS2 or ERAL1 [5, 9, 14], but these 
are the genes with fewer known cases. Molecular char-
acterization of novel cases is needed to progress in find-
ing correlations. Here we report a Spanish familial case of 
Perrault syndrome with neurological manifestations and 
show it is caused by two compound heterozygous muta-
tions in the TWNK gene, one of which is novel whereas 
the other was previously reported in a case of hepatocer-
ebral syndrome. Implications of these findings in the gen-
otype–phenotype correlations of TWNK mutations are 
discussed.
Methods
Affected subjects from family SH19 were clinically exam-
ined by the Departments of Pediatrics and Neurology of 
Hospital Universitario Central de Asturias. The genetic 
study was performed in parallel by the Service of Genet-
ics of the Hospital Universitario Ramón y Cajal, and by 
the Neurogenetics Unit of the Research Institute Ger-
mans Trias i Pujol (IGTP) in Badalona (Barcelona).
DNA was extracted from peripheral blood samples 
from all members of each family by standard methods. 
Microsatellite markers flanking the genes involved in 
PRLTS were chosen from the literature [21] and elec-
tronic databases [22] (Table 2), and were amplified using 
fluorescently-labeled primers and PCR conditions as pre-
viously reported. Amplified alleles were resolved by capil-
lary electrophoresis in an ABI Prism 3100 Avant Genetic 
Analyzer (Applied Biosystems).
Whole-exome sequencing (WES) was performed on 
genomic DNA obtained from peripheral blood. Exome 
capture was performed using SureSelect All Human 
Enrichment Target Exon (Agilent Technologies) for 
71 Mb according to the manufacturer’s protocol. Paired-
end, 101-nt long reads were generated on a HiSeq 2000 
get further insight into the genotype–phenotype correlations of a phenotypic continuum encompassing Perrault 
syndrome, infantile‑onset spinocerebellar ataxia, and hepatocerebral syndrome.
Keywords: Perrault syndrome, Hearing impairment, Polyneuropathy, Ataxia, Premature ovarian failure, TWNK, 
Mitochondrial DNA helicase
Table 1 Genes known to be involved in Perrault syndrome
Genetic type MIM entry Gene Gene MIM entry Location
PRLTS1 233400 HSD17B4 601860 5q23.1
PRLTS2 614926 HARS2 600783 5q31.3
PRLTS3 614129 CLPP 601119 19p13.3
PRLTS4 615300 LARS2 604544 3p21.31
PRLTS5 616138 TWNK 606075 10q24.31
PRLTS6 617565 ERAL1 607435 17q11.2
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platform (Illumina Inc.). Read alignment was performed 
using BWA (Burrows-Wheeler Aligner) [23]. Variant 
calling was performed using a combination of two differ-
ent algorithms: VarScan [24] and GATK [25]. Identified 
variants were annotated using the Ensembl database [26]. 
Variants with a minor allele frequency ≥ 1% in genetic 
databases including the Exome Aggregation Consor-
tium, 1000-Genomes Project and dbSNP, were excluded 
from further analysis. The genetic heterogeneity model 
proposed by Ng et al. [27] was applied in order to iden-
tify potential candidate genes. Candidate variants were 
assessed for their computationally predicted pathogenic-
ity by SIFT, PolyPhen-2, and MutationTaster [28–30], and 
prioritized in accordance with the clinical characteristics 
shared by affected siblings. Segregation of candidate vari-
ants was confirmed by Sanger sequencing.
Primer sequences for PCR amplification of all exons 
and exon–intron boundaries of the TWNK gene are 
listed in Table 3.
Mutation nomenclature is annotated based on cDNA 
sequence (GenBank accession number NM_021830.4) 
and according to the current Human Genome Varia-
tion Society rules as implemented by the Mutalyzer 2.0.3 
program (Leiden University Medical Center, Leiden, The 
Netherlands).
Results
Family SH19 included four siblings who were born from 
non-consanguineous parents (Fig. 1a). The eldest brother 
(subject II:1) died from purulent meningitis at age 
21 months. The remaining three siblings (two sisters, one 
brother) shared similar clinical features, including spi-
nocerebellar ataxia, polyneuropathy, sensorineural hear-
ing impairment, and gonadal dysfunction in females, as 
detailed below.
Subject II:2. At age 5  years, she developed a progres-
sive hearing loss leading to profound bilateral deafness 
by age 15. At age 20, her menses ceased, but the subse-
quent gynaecological study did not result in an etiologic 
diagnosis. At age 35 she started to experience difficulties 
with walking, but she did not visit a neurologist until age 
43. On examination we confirmed a profound hearing 
impairment, and found fast horizontal and vertical nys-
tagmus. Standing and gait were unstable, and she was not 
able to perform tandem gait. Romberg test was positive. 
She had cavus feet and universal areflexia. Touch and 
arthrokinetic sensitivity were diminished in lower limbs 
with a distal gradient, whereas the algesic and vibratory 
sensitivities were preserved. Over time, gait became 
impaired and showed ataxic features. There was also an 
impairment of arthrokinetic sensitivity in upper limbs. 
Table 2 Microsatellite markers that map close to the genes 
involved in PRLTS
Gene Microsatellite markers
HSD17B4 D5S404, D5S494, D5S471, D5S503
HARS2 D5S2116, D5S658, D5S2010
CLPP D19S1034, D19S427, D19S406, D19S873
LARS2 D3S3624, D3S3582, D3S1581
TWNK D10S192, D10S1265, D10S1697
ERAL1 D17S1878, D17S925, D17S1873
Table 3 Primers for PCR amplification of TWNK exons and exon–intron boundaries
F forward, R reverse
Exon Sequence of primers Annealing temperature (°C) Amplicon 
size (bp)
1 (part 1) F: 5′‑CTA AGC AGC GAG GAG AGG GGG‑3′
R: 5′‑TCG CCA CGT CCT TCT ACA AT‑3′
63 543
1 (part 2) F: 5′‑GAG GAC GAC GAG GAG ATG CTGTG‑3′
R: 5′‑CCC ATG CCC CCG CAA ATA C‑3′
63 571
1 (part 3) F: 5′‑TGC GTG GGG AGT GGA TGG ‑3′
R: 5′‑GCT GGG TCG GGG AAT AGT GGT‑3′
63 677
1 (part 4) F: 5′‑GTG TGC GAT ATC TGC GAC CTG‑3′
R: 5′‑CAT TGT CAT GGC CCA AAC CC‑3′
63 746
2 F: 5′‑TTT GGG CCA TGA CAA TGT T‑3′
R: 5′‑GGA GAT GGG GGA GTT CCT AC‑3′
60 467
3 F: 5′‑CTT CTG CCT GGG GTG GTC ‑3′
R: 5′‑TCC ATA CAT CCT GCT GCC ATAC‑3′
60 348
4 F: 5′‑GTA TGG CAG CAG GAT GTA TGGA‑3′
R: 5′‑TGT TCG GAT GGA CAG TCA AGA‑3′
60 413
5 F: 5′‑CCT CTC CCC ATT CTT ATC ACT‑3′
R: 5′‑AGC TCA GGA CCA CAG GAT AG‑3′
60 518
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Fig. 1 Genetic study of family SH19. a Pedigree, haplotype analysis for microsatellite markers and segregation of mutations in the TWNK gene. 
b Electropherograms of the two heterozygous mutations that were found in TWNK in the family. c Alignment of twinkle orthologous sequences 
from five model organisms: human (accession number NP_068602.2), mouse (NP_722491.2), cat (XP_003994377.1), chick (NP_001026515.1), and 
zebrafish (NP_001264527.1). Only stretches aligning to human twinkle residues 614–644 are shown. Asterisks indicate identical residues across 
all sequences; colons, conserved positions (residues of strongly similar properties); periods, semi‑conserved positions (residues of weakly similar 
properties). The location of the residue affected by the p.Ser629Phe mutation is indicated by an arrowhead
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Later on we found global hypotony and mild atrophy in 
the four limbs, as well as dysarthria. Neuroimaging stud-
ies found a thinning of the spinal cord, cerebellar atrophy 
and signal changes in the cerebellar white matter.
Subject II:3. At age 3  years, she developed a progres-
sive sensorineural hearing loss leading to profound bilat-
eral deafness by age 13. At age 32, she suffered a traffic 
accident that resulted in a traumatic head injury, with 
no sequels. Soon after, her menses ceased. At age 43 she 
visited the neurologist because of difficulties with walk-
ing. We confirmed the profound hearing impairment, 
and found dysarthria, global hypotony, universal areflexia 
and loss of arthrokinetic sensitivity in the feet, which 
were cavus. There was dysmetria in cerebellar manoeu-
vres with lower limbs, and she was unable to perform 
tandem gait. Neurophysiologic studies found conduc-
tion defects bilaterally in the auditory pathways, in the 
right visual pathway, and in the somesthetic pathway at 
the posterior spinal cords for afferents from both lower 
and upper limbs. Electroneurography showed symmet-
ric demyelinating sensitive polyneuropathy. Brain MRI 
showed global cerebellar atrophy and signal changes in 
the cerebellar white matter, particularly in the middle 
cerebellar peduncle. The patient has also been diagnosed 
with autoimmune hypothyroidism secondary to Hashi-
moto thyroiditis, vitiligo and increase of liver enzymes of 
unknown cause.
Subject II:4. He was diagnosed with sensorineural 
hearing loss at age 4 years. Progressive ataxia manifested 
at about age 20. He suffered a syncope at age 29, and was 
examined by a neurologist for the first time. CT scan and 
video-EEG were normal. On examination we found verti-
cal and horizontal nystagmus, universal areflexia and loss 
of arthrokinetic sensitivity in the feet, which were cavus. 
Gait was unstable, and he was unable to perform tandem 
gait. Romberg test is positive. Endocrinologic blood tests 
showed autoimmune hypothyroidism and dysfunction 
of the gonadal axis. MRI showed cervical kyphosis, flat-
tening of the spinal cord and cerebellar atrophy (Fig. 2). 
Neurophysiologic studies confirmed a profound senso-
rineural hearing impairment and found a dysfunction of 
somatosensory pathway in the posterior spinal cord and 
bulbo-cortical lemniscus. Electroneurography showed 
mixed sensitive and motor demyelinating and axonal pol-
yneuropathy, including large and small myelinic fibers.
The patients’ mother (I:2) had been diagnosed with 
Parkinson’s disease, and the father (I:1) had cavus feet. 
Family history did not show any other relative with simi-
lar traits.
The genetic study was requested in parallel to the Ser-
vice of Genetics of Hospital Universitario Ramón y Cajal 
(HURyC), because of the hearing impairment, and to the 
Functional and Translational Neurogenetics Unit (Health 
Sciences Research Institute Germans Trias i Pujol) 
(IGTP), because of the neurological signs that were 
observed.
In the HURyC, the clinical entity observed in this fam-
ily was classified as a syndromic hearing impairment. The 
association of clinical signs in the three affected siblings 
was compatible with a diagnosis of autosomal recessive 
Perrault syndrome with neurological manifestations. 
Accordingly, all five subjects in the pedigree were geno-
typed for 20 microsatellite markers that map closely to 
the six genes known to be involved in PRLTS (Table 2). 
Haplotype analysis excluded linkage to HSD17B4, 
HARS2, CLPP, LARS2 and ERAL1, but showed that the 
three siblings were haploidentical for markers close to 
TWNK (Fig.  1a). Sanger DNA sequencing of all exons 
and exon–intron boundaries of the TWNK gene revealed 
two potentially pathogenic sequence variants, c.85C>T 
(p.Arg29*) and c.1886C>T (p.Ser629Phe) (Fig.  1b), 
which were shared by the three siblings. Segregation 
analysis confirmed that the two mutations were in trans, 
the father carrying c.85C>T and the mother carrying 
c.1886C>T (Fig. 1a).
In the IGTP, the genetic cause of the polyneuropathy 
that was observed in the affected siblings was investi-
gated by massively-parallel DNA sequencing. WES of 
subject II:3, with a ≥ 20× average coverage of 88.7% of 
the target regions, identified 72,511 variants within 1396 
candidate genes under a recessive model of inheritance. 
Upon excluding those DNA variants with a minor allele 
frequency ≥ 1% in known databases, variants were pri-
oritized by their predicted deleterious effect, amino acid 
conservation, and associated disease heritability. Six of 
these candidate variants were located in genes related 
to ataxia phenotype including ATM, GALC, SPTBN2, 
SYNE1, and TWNK (Additional file  1: Table  S1). The 
best candidate variants were identified within the TWNK 
gene, c.1886C>T (p.Ser629Phe), a missense mutation that 
is predicted as pathogenic by all bioinformatic algorithms 
(SIFT score = 0.04, deleterious; PolyPhen-2 score = 0.96, 
damaging; MutationTaster score = 1, disease-causing) 
[28–30], and the nonsense mutation c.85C>T (p.Arg29*). 
Sanger sequencing confirmed the two sequence variants 
and showed the expected pattern of segregation in the 
family under a recessive mode of inheritance (Fig. 1a).
Mutation p.Arg29* is expected to result in a very small 
truncated protein lacking both domains of Twinkle, pri-
mase-related and helicase, or in no protein at all because 
of mRNA degradation through nonsense-mediate decay. 
Mutation p.Ser629Phe has not been reported previously 
in any database, it affects a highly-conserved residue 
(Fig.  1c), and it lies at the C-terminal part of the heli-
case domain, in a region where other mutations causing 
PRLTS have been reported [8, 13].
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Discussion
Most patients with rare diseases face diagnostic delays, 
because of the difficulties in noticing the association of 
clinical signs that define their particular disease [31]. In 
Perrault syndrome, diagnosis is further complicated by 
the variable expressivity of its clinical features, which 
is related to the age and sex of the patient, and to the 
diversity of genes that are involved. This is well illus-
trated by the familial case that we report here. Hearing 
loss was the first manifestation of the disease. It started 
in childhood (ages 3–5  years in the different patients) 
and it progressed quickly to become profound during 
the second decade of life. At that moment, the patients 
received a diagnosis of non-syndromic hearing impair-
ment. The second clinical sign was the early cessation of 
menses in the two affected females, which took place at 
ages 20 and 32 years, respectively. However, the possible 
association of hearing loss and early amenorrhea was not 
noticed at that time. Neurological signs manifested later 
(ages 35 and 43 in the two women, respectively, and age 
20 years in the male). Subsequently, genetic studies were 
requested, and only when the molecular results were 
Fig. 2 MRI images from subject II:4. a T2‑weighted coronal slide showing normal brain parenchyma including brain stem, the inner ears and the 
vestibulocochlear nerves. b T1‑weighted transversal slide of the dorsal spine where flattening of the spinal cord can be seen. c T2‑weighted sagittal 
slide showing cervical kyphosis as well as cerebellar and cervical atrophy. d Detail of the sagittal slide to show the cerebellar atrophy more clearly
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obtained, the diagnosis of Perrault syndrome with neu-
rological signs could be established. The same situation is 
observed in other patients with PRLTS [2]. Neurological 
signs can remain absent for years or never manifest. Male 
patients without neurological signs and without affected 
female relatives will be diagnosed of non-syndromic 
hearing loss, with the subsequent risk of having descend-
ants with the syndrome. The association of hearing loss, 
ataxia and polyneuropathy that is found in some male 
patients is also observed in a large list of other neurologi-
cal diseases [32]. On the other hand, the association of 
clinical signs could be just coincidental and not etiologi-
cally related [33].
Genetic testing can contribute to clarify the diagnosis, 
but it is also complicated by the genetic heterogeneity 
of PRLTS [34]. In spite of the identification of six genes 
whose mutations cause PRLTS, genetic testing for these 
genes does not elucidate about 60% of the clinically-
diagnosed cases [2]. Although some of the cases might 
be just coincidental associations of signs and not true 
PRLTS [33], it seems clear that other genes remain to 
be identified. Moreover, establishing genotype–pheno-
type correlations with the existing data is still hampered 
by the small number of cases carrying mutations in each 
gene (Table  4). Neurological signs have been reported 
in patients with PRLTS and mutations in the HSD17B4, 
TWNK, CLPP and LARS2 genes [4, 7, 8, 10–16, 20; and 
this work]. For CLPP and LARS2, there are also reports of 
patients without neurological signs [6, 7, 12, 14, 17–19], 
like all the patients with mutations in HARS2 or ERAL1 
who have been reported to date [5, 9, 14]. However, it 
would be premature to define genotype–phenotype cor-
relations on these bases, as the picture could change after 
careful follow-up of the already reported patients over 
the years, and after novel reports of cases with mutations 
in HARS2 or ERAL1, still underrepresented. Moreo-
ver, different mutations in some of the six PRLTS genes 
may result in other diseases. For example, mutations in 
LARS2 have been reported to cause hydrops, lactic aci-
dosis, sideroblastic anemia, and multisystem failure in a 
female newborn [35]. Also, different mutations in TWNK 
have been reported in autosomal dominant progressive 
external ophthalmoplegia (AdPEO, MIM 609286) and in 
three autosomal recessive disorders.
The TWNK gene codes for the 684-aa monomer of 
the mitochondrial DNA helicase twinkle, which local-
izes to the mitochondrial matrix and is thought to play 
a key role in mtDNA replication [36, 37]. The enzyme is 
a ring-shaped homohexamer, each monomer containing 
a primase-related domain (residues 79–346), a helicase 
domain (residues 384–635) and a linker region between 
these two domains [38]. The linker region is criti-
cal for hexamerization and helicase activity [39]. Most 
mutations causing AdPEO are missense and affect resi-
dues either within the linker or in close proximity to it in 
the tertiary structure of the protein [40, 41]. They lead to 
either destabilization of the monomers (flexibility of the 
linker region is diminished) or to defective hexameriza-
tion (inhibition of the ring closure or changing the num-
ber of subunits within the ring), which in turn impair the 
helicase activity and cause replication stalling [40, 41]. On 
the other hand, recessive mutations include a few trun-
cating variants, including deletions causing frameshifts, 
nonsense and splice-site mutations (to our knowledge, 
p.Arg29* is the first reported truncating mutation in a 
patient with PRLTS). However, the majority of recessive 
mutations are missense, some of them affecting residues 
in the primase-related domain, but most of them affect-
ing the helicase domain (like p.Ser629Phe in our patients) 
[42]. They result in three different phenotypes: Perrault 
syndrome type 5 (MIM 606075) [8], infantile-onset spi-
nocerebellar ataxia (IOSCA) [43] and hepatocerebral 
syndrome [44], although the last two disorders are now 
grouped under a unique code (MIM 271245). In fact, the 
three diseases constitute a phenotypic continuum rang-
ing from the relatively milder form (PRLTS5) to the most 
severe form (hepatocerebral syndrome, with acute liver 
failure). Hearing impairment is reported in patients of 
the three conditions, and ovarian insufficiency may be 
also a shared feature if not masked by a premature lethal-
ity. Therefore, classification of cases depends on the age 
of onset and severity of other clinical signs. In IOSCA 
and hepatocerebral syndrome, the neurological signs 
manifest in early childhood [42–44], whereas in PRLTS5 
the onset takes place much later in life [8, 12–14], as also 
shown in patients of family SH19. In hepatocerebral syn-
drome, the liver is severely affected [44]. Of note, subject 
II:3 of family SH19 shows an increase of liver enzymes of 
unknown cause. The existence of this phenotypic con-
tinuum is also supported by the spectrum of mutations 
in the TWNK gene. Whereas there is no overlap between 
the mutations causing dominant or recessive phenotypes, 
this overlap does exist among the recessive diseases [42]. 
For example, mutation p.Tyr508Cys has been reported 
in cases of IOSCA (it is a founder mutation in Finland) 
[43], but also in hepatocerebral syndrome [44, 45]. More-
over, mutation p.Arg29* has been reported in a case 
of hepatocerebral syndrome [45] and in PRLTS5 (this 
work). It is remarkable that a child with hepatocerebral 
syndrome is compound heterozygous for p.Arg29* (also 
seen in PRLTS5) (this work) and p.Tyr508Cys (frequent 
in IOSCA) [45]. It is clear that clinical and genetic char-
acterization of additional patients, like those reported 
here, is needed to progress in understanding the geno-
type–phenotype correlations in subjects with mutations 
in TWNK.
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Conclusions
Genetic testing is a useful tool to confirm a tentative clin-
ical diagnosis of Perrault syndrome, although the genetic 
cause remains unidentified in over half of the cases. Stud-
ies on genotype–phenotype correlation from the hitherto 
reported cases indicate that all patients with Perrault 
syndrome caused by TWNK mutations will manifest neu-
rological signs in adulthood. Recessive disorders caused 
by TWNK mutations constitute a phenotypic continuum, 
so that establishing genotype–phenotype correlations is a 
challenging task that still needs identification and molec-
ular and clinical characterization of novel cases.
Table 4 Overall identified mutations causing Perrault syndrome
Gene (accession number) Mutation References
DNA level Protein level






12‑kb deletion (exons 10–13) [10]
HARS2 (NM_012208.3) c.598C>G p.Leu200Val [5]
c.1010A>G p.Tyr337Cys [14]
c.1102G>T p.Val368Leu [5]










Deletion of several exons [16]






c.1565C>A p.Thr522Asn [6, 12, 19]
c.1886C>T p.Thr629Met [6, 14]
c.1912G>A p.Glu638Lys [18]









c.1886C>T p.Ser629Phe This work
ERAL1 (NM_005702.3) c.707A>T p.Asn236Ile [9]
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